Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts

Markos Leggas, Clinton F. Stewart, Michael H. Woo, Maryam Fouladi, Pamela J. Cheshire, Jennifer K. Peterson, Henry S. Friedman, Catherine Billups, Peter J Houghton

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Irofulven is a novel, small molecular weight semisynthetic compound, derived from a family of mushroom toxins known as illudins. This DNA alkylating agent has a chemical structure unlike any other chemotherapeutic agent in clinical use. The molecule is currently being studied in several Phase I, II, and III trials. The objectives of this study were to evaluate the antitumor activity of Irofulven in a panel of 20 pediatric solid tumor xenografts and to relate the Irofulven systemic exposure, defined as area under the concentration time curve, to the antitumor dose associated with tumor regression in the tumor models. Irofulven was administered i.v. daily for 5 days with courses repeated every 21 days for a total of three cycles. The minimum effective dose of Irofulven causing objective regression (≥50% volume regression) of advanced tumors was determined for each of 19 of 20 independently derived tumor models (12 brain tumors, 4 neuroblastomas, and 4 rhabdomyosarcomas). At the maximum tolerated dose for three cycles of treatment (4.6 mg/ kg/day) objective regressions were determined in 14 of 18 tumor lines (78%). However, the dose-response relationship was acute. At 2 mg/kg only 3 of 15 tumors tested demonstrated objective regressions, and in 3 additional tumors volume regressions were not achieved at a higher dose level (3 mg/kg), hence were not additionally tested. After administering the maximum tolerated dose (tolerated for one or two cycles of treatment) of Irofulven, 7 mg/kg, to mice bearing sensitive and resistant human tumors plasma concentration-time profiles were determined. Tumors were highly sensitive to Irofulven, but the systemic exposure required for a significant rate of objective response in this panel of tumors is in excess of that achievable in patients at tolerable doses, using this schedule of drug administration.

Original languageEnglish (US)
Pages (from-to)3000-3007
Number of pages8
JournalClinical Cancer Research
Volume8
Issue number9
StatePublished - Sep 1 2002
Externally publishedYes

Fingerprint

Heterografts
Neoplasms
Maximum Tolerated Dose
Drug Administration Schedule
irofulven
Rhabdomyosarcoma
Agaricales
Alkylating Agents
Tumor Burden
Neuroblastoma
Brain Neoplasms
Molecular Weight
Pediatrics
DNA
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Leggas, M., Stewart, C. F., Woo, M. H., Fouladi, M., Cheshire, P. J., Peterson, J. K., ... Houghton, P. J. (2002). Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clinical Cancer Research, 8(9), 3000-3007.

Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. / Leggas, Markos; Stewart, Clinton F.; Woo, Michael H.; Fouladi, Maryam; Cheshire, Pamela J.; Peterson, Jennifer K.; Friedman, Henry S.; Billups, Catherine; Houghton, Peter J.

In: Clinical Cancer Research, Vol. 8, No. 9, 01.09.2002, p. 3000-3007.

Research output: Contribution to journalArticle

Leggas, M, Stewart, CF, Woo, MH, Fouladi, M, Cheshire, PJ, Peterson, JK, Friedman, HS, Billups, C & Houghton, PJ 2002, 'Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts', Clinical Cancer Research, vol. 8, no. 9, pp. 3000-3007.
Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK et al. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clinical Cancer Research. 2002 Sep 1;8(9):3000-3007.
Leggas, Markos ; Stewart, Clinton F. ; Woo, Michael H. ; Fouladi, Maryam ; Cheshire, Pamela J. ; Peterson, Jennifer K. ; Friedman, Henry S. ; Billups, Catherine ; Houghton, Peter J. / Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 9. pp. 3000-3007.
@article{e43c828f41fc43ed8662e7074b10b1fa,
title = "Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts",
abstract = "Irofulven is a novel, small molecular weight semisynthetic compound, derived from a family of mushroom toxins known as illudins. This DNA alkylating agent has a chemical structure unlike any other chemotherapeutic agent in clinical use. The molecule is currently being studied in several Phase I, II, and III trials. The objectives of this study were to evaluate the antitumor activity of Irofulven in a panel of 20 pediatric solid tumor xenografts and to relate the Irofulven systemic exposure, defined as area under the concentration time curve, to the antitumor dose associated with tumor regression in the tumor models. Irofulven was administered i.v. daily for 5 days with courses repeated every 21 days for a total of three cycles. The minimum effective dose of Irofulven causing objective regression (≥50{\%} volume regression) of advanced tumors was determined for each of 19 of 20 independently derived tumor models (12 brain tumors, 4 neuroblastomas, and 4 rhabdomyosarcomas). At the maximum tolerated dose for three cycles of treatment (4.6 mg/ kg/day) objective regressions were determined in 14 of 18 tumor lines (78{\%}). However, the dose-response relationship was acute. At 2 mg/kg only 3 of 15 tumors tested demonstrated objective regressions, and in 3 additional tumors volume regressions were not achieved at a higher dose level (3 mg/kg), hence were not additionally tested. After administering the maximum tolerated dose (tolerated for one or two cycles of treatment) of Irofulven, 7 mg/kg, to mice bearing sensitive and resistant human tumors plasma concentration-time profiles were determined. Tumors were highly sensitive to Irofulven, but the systemic exposure required for a significant rate of objective response in this panel of tumors is in excess of that achievable in patients at tolerable doses, using this schedule of drug administration.",
author = "Markos Leggas and Stewart, {Clinton F.} and Woo, {Michael H.} and Maryam Fouladi and Cheshire, {Pamela J.} and Peterson, {Jennifer K.} and Friedman, {Henry S.} and Catherine Billups and Houghton, {Peter J}",
year = "2002",
month = "9",
day = "1",
language = "English (US)",
volume = "8",
pages = "3000--3007",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts

AU - Leggas, Markos

AU - Stewart, Clinton F.

AU - Woo, Michael H.

AU - Fouladi, Maryam

AU - Cheshire, Pamela J.

AU - Peterson, Jennifer K.

AU - Friedman, Henry S.

AU - Billups, Catherine

AU - Houghton, Peter J

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Irofulven is a novel, small molecular weight semisynthetic compound, derived from a family of mushroom toxins known as illudins. This DNA alkylating agent has a chemical structure unlike any other chemotherapeutic agent in clinical use. The molecule is currently being studied in several Phase I, II, and III trials. The objectives of this study were to evaluate the antitumor activity of Irofulven in a panel of 20 pediatric solid tumor xenografts and to relate the Irofulven systemic exposure, defined as area under the concentration time curve, to the antitumor dose associated with tumor regression in the tumor models. Irofulven was administered i.v. daily for 5 days with courses repeated every 21 days for a total of three cycles. The minimum effective dose of Irofulven causing objective regression (≥50% volume regression) of advanced tumors was determined for each of 19 of 20 independently derived tumor models (12 brain tumors, 4 neuroblastomas, and 4 rhabdomyosarcomas). At the maximum tolerated dose for three cycles of treatment (4.6 mg/ kg/day) objective regressions were determined in 14 of 18 tumor lines (78%). However, the dose-response relationship was acute. At 2 mg/kg only 3 of 15 tumors tested demonstrated objective regressions, and in 3 additional tumors volume regressions were not achieved at a higher dose level (3 mg/kg), hence were not additionally tested. After administering the maximum tolerated dose (tolerated for one or two cycles of treatment) of Irofulven, 7 mg/kg, to mice bearing sensitive and resistant human tumors plasma concentration-time profiles were determined. Tumors were highly sensitive to Irofulven, but the systemic exposure required for a significant rate of objective response in this panel of tumors is in excess of that achievable in patients at tolerable doses, using this schedule of drug administration.

AB - Irofulven is a novel, small molecular weight semisynthetic compound, derived from a family of mushroom toxins known as illudins. This DNA alkylating agent has a chemical structure unlike any other chemotherapeutic agent in clinical use. The molecule is currently being studied in several Phase I, II, and III trials. The objectives of this study were to evaluate the antitumor activity of Irofulven in a panel of 20 pediatric solid tumor xenografts and to relate the Irofulven systemic exposure, defined as area under the concentration time curve, to the antitumor dose associated with tumor regression in the tumor models. Irofulven was administered i.v. daily for 5 days with courses repeated every 21 days for a total of three cycles. The minimum effective dose of Irofulven causing objective regression (≥50% volume regression) of advanced tumors was determined for each of 19 of 20 independently derived tumor models (12 brain tumors, 4 neuroblastomas, and 4 rhabdomyosarcomas). At the maximum tolerated dose for three cycles of treatment (4.6 mg/ kg/day) objective regressions were determined in 14 of 18 tumor lines (78%). However, the dose-response relationship was acute. At 2 mg/kg only 3 of 15 tumors tested demonstrated objective regressions, and in 3 additional tumors volume regressions were not achieved at a higher dose level (3 mg/kg), hence were not additionally tested. After administering the maximum tolerated dose (tolerated for one or two cycles of treatment) of Irofulven, 7 mg/kg, to mice bearing sensitive and resistant human tumors plasma concentration-time profiles were determined. Tumors were highly sensitive to Irofulven, but the systemic exposure required for a significant rate of objective response in this panel of tumors is in excess of that achievable in patients at tolerable doses, using this schedule of drug administration.

UR - http://www.scopus.com/inward/record.url?scp=0036716830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036716830&partnerID=8YFLogxK

M3 - Article

C2 - 12231547

AN - SCOPUS:0036716830

VL - 8

SP - 3000

EP - 3007

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -